文献速递肝病消化道肿瘤与早癌

核糖核酸酶7驱动ROS1激活是肝细胞癌的潜在治疗靶点

Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2020-10-05

本研究探讨ROS1在肝细胞癌中的病理生理作用及ROS1靶向治疗的效用。RNase7与ROS1的N3-P2结构域结合并促进ROS1介导的致癌转化,肝细胞癌患者血浆RNase7水平高于健康人,高ROS1和RNase7表达与不良预后相关。在肝细胞癌PDX和原位小鼠模型中,ROS1抑制剂治疗显著抑制RNase7诱导的肿瘤发生。

要点

  • RNase7是ROS1的高亲和力配体,与ROS1的N3-P2结构域结合。
  • 肝细胞癌患者血浆RNase7水平高于健康个体,高ROS1和RNase7表达与不良预后相关。
  • ROS1抑制剂在PDX和原位小鼠模型中抑制RNase7诱导的肿瘤发生。

核心结论

  • RNase7是ROS1的高亲和力配体,血浆RNase7可作为生物标志物识别可能从抗ROS1治疗中获益的肝细胞癌患者。
  • 抗ROS1抑制剂可用于治疗RNase7水平高的肝细胞癌患者。

研究设计与样本

  • 纯化重组核糖核酸酶,在肝细胞癌细胞系中通过Duolink、免疫荧光和免疫沉淀 assays 验证RNase7与ROS1的配体-受体关系。
  • 使用蛋白-蛋白对接方法预测ROS1与RNase7之间潜在的相互作用残基。
  • 通过细胞增殖、迁移和侵袭实验以及异种移植小鼠模型分析RNase7的致癌功能。
  • 在患者来源异种移植(PDX)和原位模型中评估抗ROS1抑制剂治疗的疗效。
  • 分析两个独立患者队列以评估RNase7/ROS1的病理相关性。

主要发现

  • RNase7与ROS1的N3-P2结构域结合并促进ROS1介导的致癌转化。
  • 肝细胞癌患者血浆RNase7水平高于健康个体。
  • 高ROS1和RNase7表达与肝细胞癌患者不良预后密切相关。
  • 在肝细胞癌PDX和原位小鼠模型中,ROS1抑制剂治疗显著抑制RNase7诱导的肿瘤发生,导致小鼠血浆RNase7水平降低和肿瘤缩小。

临床怎么用

  • 作者认为,血浆RNase7可作为生物标志物用于识别可能从抗ROS1治疗中获益的肝细胞癌患者。
  • 作者认为,抗ROS1抑制剂可用于治疗RNase7水平高的肝细胞癌患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are currently limited therapeutic options for hepatocellular carcinoma (HCC), particularly when it is diagnosed at advanced stages. Herein, we examined the pathophysiological role of ROS1 and assessed the utility of ROS1-targeted therapy for the treatment of HCC. METHODS: Recombinant ribonucleases (RNases) were purified, and the ligand-receptor relationship between RNase7 and ROS1 was validated in HCC cell lines by Duolink, immunofluorescence, and immunoprecipitation assays. Potential interacting residues between ROS1 and RNase7 were predicted using a protein-protein docking approach. The oncogenic function of RNase7 was analyzed by cell proliferation, migration and invasion assays, and a xenograft mouse model. The efficacy of anti-ROS1 inhibitor treatment was evaluated in patient-derived xenograft (PDX) and orthotopic models. Two independent patient cohorts were analyzed to evaluate the pathological relevance of RNase7/ROS1. RESULTS: RNase7 associated with ROS1's N3-P2 domain and promoted ROS1-mediated oncogenic transformation. Patients with HCC exhibited elevated plasma RNase7 levels compared with healthy individuals. High ROS1 and RNase7 expression were strongly associated with poor prognosis in patients with HCC. In both HCC PDX and orthotopic mouse models, ROS1 inhibitor treatment markedly suppressed RNase7-induced tumorigenesis, leading to decreased plasma RNase7 levels and tumor shrinkage in mice. CONCLUSIONS: RNase7 serves as a high-affinity ligand for ROS1. Plasma RNase7 could be used as a biomarker to identify patients with HCC who may benefit from anti-ROS1 treatment. LAY SUMMARY: Receptor tyrosine kinases are known to be involved in tumorigenesis and have been targeted therapeutically for a number of cancers, including hepatocellular carcinoma. ROS1 is the only such receptor with kinase activity whose ligand has not been identified. Herein, we show that RNase7 acts as a ligand to activate ROS1 signaling. This has important pathophysiological and therapeutic implications. Anti-ROS1 inhibitors could be used to treatment patients with hepatocellular carcinoma and high RNase7 levels.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu C, Zha Z, Zhou C, et al. Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. J Hepatol. 2020. PMID: 33031845. doi:10.1016/j.jhep.2020.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。